Loading...
Efficacy and safety of extended dosing schedules of CC-486 (oral azacitidine) in patients with lower-risk myelodysplastic syndromes
CC-486, the oral formulation of azacitidine (AZA), is an epigenetic modifier and DNA methyltransferase inhibitor in clinical development for treatment of hematologic malignancies. CC-486 administered for 7 days per 28-day treatment cycle was evaluated in a phase 1 dose-finding study. AZA has a short...
Na minha lista:
| Udgivet i: | Leukemia |
|---|---|
| Main Authors: | , , , , , , , , , , , , |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
Nature Publishing Group
2016
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4832070/ https://ncbi.nlm.nih.gov/pubmed/26442612 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/leu.2015.265 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|